http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109908137-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-26 |
| filingDate | 2019-03-11^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-18^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-18^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109908137-B |
| titleOfInvention | Application of artemisinin in medicine for killing breast cancer stem cells |
| abstract | The invention discloses an application of artemisinin in preparing a medicament for inhibiting or killing breast cancer tumor stem cells. The artemisinin can effectively kill breast cancer tumor stem cells, has stronger killing effect on the tumor stem cells compared with cancer cells which do not generate dry evolution, and shows selective and efficient killing on the tumor stem cells. Artemisinin has effect of inducing iron death of breast cancer stem cells, and is prepared by mixing artemisinin with Fe 3 O 4 The nanoparticles are combined, or the magnetic nanoparticles are further coupled with targets such as tyrosine kinase-like orphan receptor 1 antibodies, so that the killing effect on breast cancer stem cells is obviously improved. The invention also discloses an anti-tumor pharmaceutical composition for inhibiting or killing breast cancer tumor stem cells. The invention provides a new strategy for tumor treatment by specifically killing tumor stem cells, and has important significance for improving the tumor curative effect, reducing tumor recurrence, improving the life quality of tumor patients and prolonging the survival time. |
| priorityDate | 2019-03-11^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 174 of 174.